JP2019517528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517528A5 JP2019517528A5 JP2018563519A JP2018563519A JP2019517528A5 JP 2019517528 A5 JP2019517528 A5 JP 2019517528A5 JP 2018563519 A JP2018563519 A JP 2018563519A JP 2018563519 A JP2018563519 A JP 2018563519A JP 2019517528 A5 JP2019517528 A5 JP 2019517528A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- period
- composition
- days
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 122
- 150000003839 salts Chemical class 0.000 claims description 106
- 208000034970 Heterotopic Ossification Diseases 0.000 claims description 31
- 230000000750 progressive effect Effects 0.000 claims description 18
- 206010049811 Extraskeletal ossification Diseases 0.000 claims description 17
- 230000011164 ossification Effects 0.000 claims description 16
- 230000001387 anti-histamine Effects 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 5
- 206010015150 Erythema Diseases 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 111
- 208000024891 symptom Diseases 0.000 claims 61
- 230000000306 recurrent effect Effects 0.000 claims 35
- 206010058314 Dysplasia Diseases 0.000 claims 15
- 206010016654 Fibrosis Diseases 0.000 claims 15
- 230000004761 fibrosis Effects 0.000 claims 15
- 230000007941 heterotopic ossification Effects 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 230000000284 resting effect Effects 0.000 description 48
- 238000012423 maintenance Methods 0.000 description 24
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 4
- 208000010358 Myositis Ossificans Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- CJLMANFTWLNAKC-UHFFFAOYSA-N 3-[6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=C(O)C=CC=2)N)=C1 CJLMANFTWLNAKC-UHFFFAOYSA-N 0.000 description 2
- BBDGBGOVJPEFBT-UHFFFAOYSA-N 5-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CN=C3C=CC=2)C=C1 BBDGBGOVJPEFBT-UHFFFAOYSA-N 0.000 description 2
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- RMMCJMFEDYDIHX-UHFFFAOYSA-N 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-1h-quinolin-2-one Chemical compound C12=CC=CC=C2NC(=O)C=C1C(=C1N=C2)C=NN1C=C2C(C=C1)=CC=C1N1CCNCC1 RMMCJMFEDYDIHX-UHFFFAOYSA-N 0.000 description 1
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical group C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 1
- 229940126023 ALK2 kinase inhibitor Drugs 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021197653A JP2022019995A (ja) | 2016-06-08 | 2021-12-06 | 異所性骨化を治療するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347381P | 2016-06-08 | 2016-06-08 | |
| US62/347,381 | 2016-06-08 | ||
| PCT/CA2017/050701 WO2017210792A1 (en) | 2016-06-08 | 2017-06-08 | Methods for treating heterotopic ossification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197653A Division JP2022019995A (ja) | 2016-06-08 | 2021-12-06 | 異所性骨化を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517528A JP2019517528A (ja) | 2019-06-24 |
| JP2019517528A5 true JP2019517528A5 (enExample) | 2020-07-16 |
| JP7023868B2 JP7023868B2 (ja) | 2022-02-22 |
Family
ID=60578331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563519A Active JP7023868B2 (ja) | 2016-06-08 | 2017-06-08 | 異所性骨化を治療するための方法 |
| JP2021197653A Withdrawn JP2022019995A (ja) | 2016-06-08 | 2021-12-06 | 異所性骨化を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197653A Withdrawn JP2022019995A (ja) | 2016-06-08 | 2021-12-06 | 異所性骨化を治療するための方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10864194B2 (enExample) |
| EP (2) | EP3468554B1 (enExample) |
| JP (2) | JP7023868B2 (enExample) |
| KR (1) | KR102486607B1 (enExample) |
| CN (2) | CN109562099A (enExample) |
| AU (2) | AU2017276835B2 (enExample) |
| BR (1) | BR112018075422A2 (enExample) |
| CA (1) | CA3025854A1 (enExample) |
| CL (1) | CL2018003502A1 (enExample) |
| EA (1) | EA201892497A1 (enExample) |
| ES (1) | ES2963348T3 (enExample) |
| IL (3) | IL263440B (enExample) |
| MX (2) | MX390115B (enExample) |
| MY (1) | MY200642A (enExample) |
| PH (1) | PH12018502563A1 (enExample) |
| SG (1) | SG11201810658PA (enExample) |
| WO (1) | WO2017210792A1 (enExample) |
| ZA (1) | ZA201808102B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773213B (zh) | 2010-09-01 | 2023-02-24 | 托马斯杰弗逊大学 | 用于肌肉修复和再生的组合物和方法 |
| ES2963348T3 (es) * | 2016-06-08 | 2024-03-26 | Clementia Pharmaceuticals Inc | Métodos para tratar la osificación heterotópica |
| JP7018957B2 (ja) | 2016-11-16 | 2022-02-14 | クレメンティア ファーマシューティカルズ インコーポレイテッド | 多発性骨軟骨腫（ｍｏ）を処置するための方法 |
| WO2020118405A1 (en) * | 2018-12-13 | 2020-06-18 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
| EP4186505A4 (en) * | 2020-06-11 | 2024-06-19 | Yang Sheng Tang Company, Ltd. | USE OF PALOVAROTEN TO TREAT HBV VIRUS |
| EP4470537A1 (en) * | 2023-05-30 | 2024-12-04 | Queen's University At Kingston | Compound for use in treating fibrodysplasia ossificans progressiva (fop) |
| EP4470536A1 (en) * | 2023-05-30 | 2024-12-04 | Queen's University At Kingston | Compound for use in treating fibrodysplasia ossificans progressiva (fop) |
| CN119185298B (zh) * | 2024-10-30 | 2025-09-26 | 武汉大学人民医院（湖北省人民医院） | 帕罗伐汀在制备用于治疗脑出血后急性脑损伤的药物中的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824685A (en) | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| US5624957A (en) | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| US7514074B2 (en) | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
| US6204288B1 (en) | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
| US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| CA2402413A1 (en) | 2000-03-14 | 2001-09-20 | The University Of Western Ontario | Compositions and methods for affecting osteogenesis |
| WO2002028810A2 (en) | 2000-10-02 | 2002-04-11 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
| BR0212583A (pt) | 2001-09-18 | 2004-10-13 | Hoffmann La Roche | Agonistas i para retinóides de alquil uréia |
| AU2002340886B2 (en) | 2001-09-18 | 2008-01-31 | F. Hoffmann-La Roche Ag | Substituted urea retinoid agonists II |
| AUPR892501A0 (en) | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| JP2005206544A (ja) | 2004-01-23 | 2005-08-04 | Yasuyoshi Uchida | 筋肉再生剤 |
| AU2005240078A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| US20060210638A1 (en) | 2005-03-17 | 2006-09-21 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
| US7345931B2 (en) | 2005-08-01 | 2008-03-18 | Infineon Technologies Ag | Maintaining internal voltages of an integrated circuit in response to a clocked standby mode |
| US20090281184A1 (en) | 2005-09-27 | 2009-11-12 | Sapporo Medical University | Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability |
| US20070213308A1 (en) * | 2006-01-26 | 2007-09-13 | Lessem Jan N | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith |
| CA2647275A1 (en) | 2006-03-31 | 2007-10-11 | F. Hoffmann-La Roche Ag | Process for preparing retinoid compounds |
| CN101472572B (zh) | 2006-05-16 | 2012-10-10 | Io治疗有限责任公司 | Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途 |
| US8614103B2 (en) | 2006-10-27 | 2013-12-24 | Lpath, Inc. | Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| JP2009235031A (ja) | 2008-03-28 | 2009-10-15 | Nano Egg:Kk | 角膜組織の再生促進剤 |
| EP2379174A4 (en) | 2008-12-18 | 2012-11-14 | Astrazeneca Ab | PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE |
| WO2010088735A1 (en) | 2009-02-05 | 2010-08-12 | Regenertech Pty Ltd | Method of producing progenitor cells from differentiated cells |
| US20120277156A1 (en) * | 2009-07-21 | 2012-11-01 | University Of Washington Trhough It's Center For Commercialization | Inhibition of pathological bone formation |
| CN111773213B (zh) | 2010-09-01 | 2023-02-24 | 托马斯杰弗逊大学 | 用于肌肉修复和再生的组合物和方法 |
| US20120077786A1 (en) | 2010-09-27 | 2012-03-29 | Byron David A | Methods and compositions for disease treatment using inhalation |
| WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| WO2013006372A1 (en) * | 2011-07-01 | 2013-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of treating pathologic heterotopic ossification |
| US8772273B2 (en) | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
| AU2013222345B2 (en) * | 2012-02-22 | 2017-09-07 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
| JP6430383B2 (ja) | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
| WO2014073209A1 (ja) | 2012-11-08 | 2014-05-15 | 国立大学法人山口大学 | 角結膜障害の治療剤 |
| EP2964651A4 (en) | 2013-03-04 | 2016-11-30 | Brigham & Womens Hospital | BMP HEMMER AND METHOD OF USE THEREOF |
| JP6542192B2 (ja) | 2013-03-14 | 2019-07-10 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Ｂｍｐ阻害剤およびその使用方法 |
| US10702502B2 (en) | 2013-05-22 | 2020-07-07 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
| EP3201187A4 (en) * | 2014-10-01 | 2018-04-11 | The Brigham and Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
| US20180311356A1 (en) | 2015-10-19 | 2018-11-01 | The Children's Medical Center Corporation | Method to inhibit endothelial-to-mesenchymal transition |
| WO2017112431A1 (en) * | 2015-12-24 | 2017-06-29 | The Regents Of The University Of Michigan | Method of treating heterotopic ossification |
| ES2963348T3 (es) | 2016-06-08 | 2024-03-26 | Clementia Pharmaceuticals Inc | Métodos para tratar la osificación heterotópica |
| WO2020118405A1 (en) | 2018-12-13 | 2020-06-18 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
-
2017
- 2017-06-08 ES ES17809505T patent/ES2963348T3/es active Active
- 2017-06-08 IL IL263440A patent/IL263440B/en unknown
- 2017-06-08 EP EP17809505.5A patent/EP3468554B1/en active Active
- 2017-06-08 JP JP2018563519A patent/JP7023868B2/ja active Active
- 2017-06-08 EA EA201892497A patent/EA201892497A1/ru unknown
- 2017-06-08 US US16/308,012 patent/US10864194B2/en active Active
- 2017-06-08 CN CN201780035660.5A patent/CN109562099A/zh active Pending
- 2017-06-08 MY MYPI2018002302A patent/MY200642A/en unknown
- 2017-06-08 IL IL295440A patent/IL295440B2/en unknown
- 2017-06-08 SG SG11201810658PA patent/SG11201810658PA/en unknown
- 2017-06-08 MX MX2018015108A patent/MX390115B/es unknown
- 2017-06-08 IL IL317726A patent/IL317726A/en unknown
- 2017-06-08 CN CN202510415662.3A patent/CN120204216A/zh active Pending
- 2017-06-08 CA CA3025854A patent/CA3025854A1/en active Pending
- 2017-06-08 BR BR112018075422-6A patent/BR112018075422A2/pt not_active Application Discontinuation
- 2017-06-08 WO PCT/CA2017/050701 patent/WO2017210792A1/en not_active Ceased
- 2017-06-08 EP EP23189636.6A patent/EP4249490A3/en active Pending
- 2017-06-08 KR KR1020197000339A patent/KR102486607B1/ko active Active
- 2017-06-08 AU AU2017276835A patent/AU2017276835B2/en active Active
-
2018
- 2018-11-29 ZA ZA2018/08102A patent/ZA201808102B/en unknown
- 2018-12-05 PH PH12018502563A patent/PH12018502563A1/en unknown
- 2018-12-05 MX MX2022001991A patent/MX2022001991A/es unknown
- 2018-12-06 CL CL2018003502A patent/CL2018003502A1/es unknown
-
2020
- 2020-11-17 US US16/950,604 patent/US11622959B2/en active Active
-
2021
- 2021-12-06 JP JP2021197653A patent/JP2022019995A/ja not_active Withdrawn
-
2022
- 2022-03-29 AU AU2022202148A patent/AU2022202148B2/en active Active
-
2023
- 2023-03-13 US US18/182,463 patent/US12458626B2/en active Active
-
2024
- 2024-04-17 US US18/637,711 patent/US12138245B2/en active Active
- 2024-06-28 US US18/758,242 patent/US12201614B2/en active Active
-
2025
- 2025-06-18 US US19/242,219 patent/US20260021073A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5819328B2 (ja) | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 | |
| AU2022202148B2 (en) | Methods for treating heterotopic ossification | |
| KR102860817B1 (ko) | 트라디피턴트에 의한 치료 방법 | |
| EP2632458B1 (en) | Dosing regimes for the treatment of ocular vascular disease | |
| JP2014517050A5 (enExample) | ||
| TW202222318A (zh) | 與延釋帕利哌酮可注射配製物相關之投藥方案（二） | |
| CN107847491A (zh) | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 | |
| JP2023501186A (ja) | グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用 | |
| AU2015216590A1 (en) | Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer | |
| HK40006943A (en) | Methods for treating heterotopic ossification | |
| EA047841B1 (ru) | Способы лечения гетеротопической оссификации | |
| HK1224599A (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| HK1224599A1 (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| Chen | Department of Dermatology, Boston University School of Medicine, 609 Albany Street, J501, Boston, MA 02118, USA e-mail: ayyen@ alum. mit. edu DF Murrell (ed.), Clinical Cases in Autoimmune | |
| EA042153B1 (ru) | Способы лечения гетеротопической оссификации | |
| JP2017088504A (ja) | マクロファージからのｍｍｐ−９及びｍｃｐ−１分泌の阻害剤 |